Pacific GeneTech Announces New U.S. Corporate Headquarters in Northwest Arkansas

11 March, 2022 (Fayetteville, Arkansas)

Pacific GeneTech (PGT) today announced plans to locate its U.S. headquarters to Northwest Arkansas (NWA).  The new corporate headquarters will be a biotechnology and manufacturing center that will house an adjuvant manufacturing facility, vaccine development lab and management office

The company said that the decision to locate its corporate headquarters in NWA was based on the ability to attract qualified technical management and employees to one of the most vibrant and rapidly growing areas in the U.S.,  the potential for close cooperation with collaborators, such as the University of Arkansas, where the technology was derived, and the strong support by the state.

The new headquarters will provide an expanded area for the Company’s laboratory vaccine development, manufacturing of Hercules adjuvant delivery system and Aegis vaccines to enhance the Company’s service to its licensees and collaborators. This will also enable better collaboration and productivity as well as an improved corporate culture to support the Company’s growth initiatives.

 

“These are exciting times at PGT as we move into a new phase for the Company,” said Tim Collard, Chief Executive Officer of PGT. The NWA facility is expected to open in late 2022 and create new jobs in the biotechnology and animal health industries.

ABOUT PACIFIC GENETECH

Pacific GeneTech (www.pacificgenetech.com) develops and commercializes next-generation vaccines and biologics for unmet needs in food safety and animal health. PGT's proprietary "Aegis" vaccine platform combines cross-protective antigens and immunopotentiators in PGT vectors for broad spectrum protection against multiple strains and species of infectious diseases. PGT's "Hercules" adjuvant/delivery system provides enhanced efficacy of inactivated and DNA vaccines.

 

PGT has out-licensed its leading poultry vaccines addressing economically important gastro-intestinal pathogens and is developing new vaccines for other pathogens in swine and ruminants. PGT has out-licensed its adjuvant for use in third-party vaccines and is developing broad applications for its adjuvant/delivery system.

Original source: https://www.businesswire.com/news/home/20220311005122/en